trial

Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

NCTId NCT00485823
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 48 (actual)
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2002-12
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Olanzapineweight management program

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

1 total
Seoul, South Korea

Facts & assertions

3 sourced
Enrollment
48
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
weight management program
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenic Disorders
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person